Celyad Oncology EBIT

The latest EBIT for CYAD is $-15M as of December 2024. That compares with $-10K in the prior-year period — down 153130.0% year over year. That is below the Healthcare sector average of $23B. Investors often review this figure alongside Celyad Oncology's historical trend and sector peers before judging valuation or financial health.

Over the past year, CYAD's EBIT moved from $-10K to $-15M — a 153130.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Celyad Oncology's operating scale or balance-sheet position.

Against Healthcare companies, CYAD currently prints $-15M for EBIT, while the sector average sits near $23B. That is roughly 100.1% below the sector mean. Large gaps often invite a closer look at Celyad Oncology's growth, margins, and balance sheet.

A EBIT figure of $-15M for CYAD is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $23B. Explore the charts below for those layers of context.

After noting CYAD's EBIT ($-15M), review year-over-year change from $-10K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.